echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > It reveals the toxic mechanism of chromycin and develops a promising class of anti-tuberculosis drugs

    It reveals the toxic mechanism of chromycin and develops a promising class of anti-tuberculosis drugs

    • Last Update: 2021-02-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Tuberculosis (TB) is a disease caused by Mycobacterium tuberculosis, which kills about 1.3 million people worldwide each year. The vast majority of deaths occur in developing countries, where poor sanitation and poor access to health services make the problem even worse. Antibiotic resistance is becoming an important issue for TB because many pathogenic strains are resistant to a range of available drugs, and some of these strains are resistant to all of these antibiotics.
    is an antibiotic produced by several bacterial types, but it is not suitable for humans because it is also toxic to animal cells.
    a new study, researchers from research institutions such as the University of Oxford in the United Kingdom studied the toxicity formation mechanism of lysycin and found that it acted on the gene DPAGT1, which produces an enzyme involved in the biosynthetic synthesis of glycogen. The findings were recently published in the Journal of Cell under the title "Structures of DPAGT1 Explain Glycosylation Disease Mechanisms and Advance TB Antibiotic Design".
    by studying the interaction between chromycin and the protein, the researchers were able to understand how it worked on cells. They also altered the structure of chromycin to create new similarity, several of which effectively treat tuberculosis in mice.
    Professor Benjamin Davis, of the Department of Chemistry at the University of Oxford, said: "The threat of TB is growing because we are running out of drugs to treat it. An exciting result of this study is the development of a promising new class of antimicrobial drugs. (Bio Valley)
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.